Gilead Sciences, Inc. (GILD)
| Market Cap | 115.13B |
| Revenue (ttm) | 28.30B |
| Net Income (ttm) | 126.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.10 |
| PE Ratio | 913.73 |
| Forward PE | 12.56 |
| Dividend | $3.08 (3.33%) |
| Ex-Dividend Date | Dec 13, 2024 |
| Volume | 5,564,171 |
| Open | 92.46 |
| Previous Close | 92.38 |
| Day's Range | 91.44 - 93.22 |
| 52-Week Range | 62.07 - 98.90 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 96.71 (+4.69%) |
| Earnings Date | Feb 4, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $96.71, which is an increase of 4.69% from the latest price.
News
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will bec...
Final Trade: LMAT, GOOGL, IBM, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleuc...
Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabt...
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcome...
Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 11:40 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call P...
Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 11:00 AM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Particip...
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
FOSTER CITY, Calif & MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and dev...
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company's pivotal Phase 3 PURP...
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.
BETHESDA, Md.--(BUSINESS WIRE)--The Children's Inn at the National Institutes of Health (NIH) today announced that Gilead Sciences Inc. has awarded The Inn a $1 million grant to support its renovation...
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ET Company Participants Dan O'Day - Chairman and CEO Andy Dickinson - CFO Conference Call Par...
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%...
Gilead Sciences to close Seattle office; shutdown impacts 72 employees
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday.
Gilead Prices $3.5 Billion of Senior Unsecured Notes
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today annou...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stud...
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a b...
Gilead Sciences: Finally Some Real Momentum
Shares of Gilead Sciences, Inc. experienced a downturn early in 2024 due to pipeline setbacks and underwhelming guidance, but shares have seen a significant recovery recently. The company's reliance o...
Gilead Sciences to Present at Upcoming Investor Engagements
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Healthca...
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead Sciences Inc GILD stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its fiscal year 2024 guidance.
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio and increased demand for COVID-19 therapy Veklury. Oncology remains a weak area, with CAR-T ...
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infec...
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript